{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":3880,"total_is_capped":false,"direct_labels_cover":13,"predictions_cover":3880,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"74551677015f","filters":{"topic":"Prostate Cancer Treatment and Research"}},"results":[{"id":"W2120292596","doi":"10.1056/nejmoa040720","title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5725,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Prednisone; Mitoxantrone; Medicine; Docetaxel; Prostate cancer; Oncology; Internal medicine; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03697808835937899,"gpt":0.3596593328284429,"spread":0.3226812444690639,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006853042,0.0003407431,0.001137954,0.0003058113,0.000138016,0.00002063899,0.0002088275,0.0001198242,0.0003014173],"category_scores_gemma":[0.0005020251,0.0001852453,0.000165595,0.0003629898,0.000236666,0.0002313812,0.00003575438,0.0005078965,0.000005140439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008930169,"about_ca_system_score_gemma":0.003253688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002504863,"about_ca_topic_score_gemma":0.0001648311,"domain_scores_codex":[0.9971821,0.00004779117,0.0008609004,0.0003146768,0.0009424689,0.000652112],"domain_scores_gemma":[0.9975838,0.0002214426,0.0004818999,0.000276668,0.0006491006,0.0007870817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2583257,0.000967663,0.003233971,0.001951977,0.002736846,0.003366605,0.01672462,0.0057308,0.07955432,0.0002627106,0.04138797,0.5857568],"study_design_scores_gemma":[0.7801051,0.02208224,0.002365065,0.00521046,0.001442388,0.002675677,0.001304016,0.0002338694,0.01884122,0.001515201,0.1638019,0.0004228724],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8209414,0.05916638,0.004900626,0.1081891,0.002415768,0.003451488,0.00009732864,0.00008320876,0.0007547077],"genre_scores_gemma":[0.932687,0.02313773,0.007569683,0.0009755599,0.01069531,0.0001248308,0.00006754069,0.0001078918,0.0246344],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5853339,"threshold_uncertainty_score":0.7554083,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2148643283","doi":"10.1056/nejmoa1207506","title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4574,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Genentech; Cilag; Astellas Pharma; Teva Pharmaceutical Industries; Eisai; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Active Biotech; Celgene; Astellas Pharma Global Development; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Oncology; Overall survival; Internal medicine; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0203892061612365,"gpt":0.3202014771681385,"spread":0.299812271006902,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009228829,0.0001552705,0.0004844263,0.0002440825,0.00001855721,0.000005375003,0.0000624683,0.00004018232,0.0006339602],"category_scores_gemma":[0.00006758347,0.00007725282,0.00004020365,0.0002659138,0.0001151155,0.000146046,0.000009030761,0.0003793964,0.000002917347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001693618,"about_ca_system_score_gemma":0.0004108075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006948122,"about_ca_topic_score_gemma":0.000182304,"domain_scores_codex":[0.9985241,0.00007985355,0.0003405785,0.00009725664,0.0005879715,0.0003702195],"domain_scores_gemma":[0.9989738,0.0001043926,0.0001428068,0.0001196719,0.00015828,0.0005010148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02033595,0.0001805472,0.9052799,0.0000664166,0.0001747156,0.00063543,0.003169748,0.000003169324,0.003310064,0.000007203932,0.0009504225,0.06588645],"study_design_scores_gemma":[0.1696256,0.002255916,0.7827547,0.001605869,0.00020376,0.0009290634,0.0004275299,0.0000075104,0.003364467,0.00006408307,0.03861561,0.0001459133],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719124,0.01428203,0.00001992837,0.01248875,0.0002783485,0.000251592,0.000002690949,0.000007039025,0.0007571829],"genre_scores_gemma":[0.9908887,0.003779998,0.0002146329,0.0006065289,0.003456356,0.00001060991,0.000004564921,0.00002471419,0.001013874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1492897,"threshold_uncertainty_score":0.6941419,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2110534364","doi":"10.1056/nejmoa1014618","title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4394,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Université de Montréal; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Hazard ratio; Internal medicine; Urology; Clinical endpoint; Placebo; Antiandrogen; Interim analysis; Adverse effect; Androgen deprivation therapy; Oncology; Randomized controlled trial; Cancer; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.06641357971523264,"gpt":0.3362644191071107,"spread":0.269850839391878,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000909924,0.0001269058,0.0005007003,0.0002742113,0.00002161324,0.000004659558,0.00005717826,0.00002821703,0.0004296564],"category_scores_gemma":[0.0001394835,0.00007003058,0.00002814989,0.0001923693,0.0001419793,0.00009458989,0.00001631614,0.000292129,0.000001655124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006776714,"about_ca_system_score_gemma":0.0003250768,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002258063,"about_ca_topic_score_gemma":0.0003060334,"domain_scores_codex":[0.9987901,0.000101239,0.0004058492,0.0001140353,0.0003672209,0.0002215503],"domain_scores_gemma":[0.9991558,0.00009031581,0.000148634,0.00009080187,0.0001454482,0.0003690615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01415754,0.0003013609,0.7102682,0.0002622573,0.0004343419,0.003876551,0.01184532,0.000001522944,0.01314425,0.00008430406,0.001715157,0.2439092],"study_design_scores_gemma":[0.2470421,0.006753054,0.7253301,0.001939446,0.0006034303,0.001518089,0.001342959,0.0000412402,0.005382008,0.001685615,0.008162842,0.000199065],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839194,0.009985796,0.00001743339,0.004460842,0.0002480523,0.0002238016,0.000003119478,0.000005723314,0.001135864],"genre_scores_gemma":[0.9921478,0.005759933,0.0004170196,0.0001928075,0.0006608884,0.000004350431,0.000003763662,0.00001482083,0.0007985862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2437101,"threshold_uncertainty_score":0.4704436,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123526148","doi":"10.1016/s0140-6736(10)61389-x","title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3284,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Cabazitaxel; Mitoxantrone; Docetaxel; Medicine; Prostate cancer; Prednisone; Internal medicine; Oncology; Taxane; Enzalutamide; Clinical endpoint; Abiraterone acetate; Hazard ratio; Randomized controlled trial; Cancer; Surgery; Chemotherapy; Androgen deprivation therapy; Confidence interval; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1328304745619498,"gpt":0.4254878231418871,"spread":0.2926573485799373,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006037885,0.0003373041,0.001029943,0.00006933357,0.0003591642,0.0003395327,0.0003200737,0.00007508929,0.0002572548],"category_scores_gemma":[0.0001449116,0.0001604896,0.0001190584,0.0002202032,0.000250816,0.0002183654,0.00007051815,0.0002695791,0.00001324724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002467706,"about_ca_system_score_gemma":0.001396514,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000376149,"about_ca_topic_score_gemma":0.001740637,"domain_scores_codex":[0.9978687,0.000118732,0.000447367,0.0004590649,0.0003619991,0.0007441259],"domain_scores_gemma":[0.9984288,0.0003167139,0.0002058463,0.0006628857,0.0001891934,0.0001966271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9469494,0.00108779,0.0001999342,0.0002900915,0.0009776769,0.0001524836,0.001655225,0.000002810788,0.02685197,0.00004141629,0.003386181,0.01840503],"study_design_scores_gemma":[0.9632098,0.0043083,0.0005372582,0.0002825309,0.001254822,0.00004609325,0.0002078233,0.001243533,0.008740637,0.0002184289,0.01965135,0.0002994141],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9603578,0.003744454,0.00003766095,0.01485089,0.0005627847,0.01892344,0.0009870243,0.00008432426,0.0004516513],"genre_scores_gemma":[0.9438868,0.0008769187,0.007240989,0.0003755431,0.002190772,0.02468047,0.000230417,0.00009136805,0.02042676],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01997511,"threshold_uncertainty_score":0.6544575,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166918329","doi":"10.1056/nejmoa1405095","title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3031,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Cliniques Universitaires Saint-Luc; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of California, Davis; Duke Cancer Institute; Astellas Pharma Global Development; Weill Cornell Medical College; Rigshospitalet; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Institut Gustave-Roussy; Astellas Pharma; Université de Montréal; University of Washington; University of Alberta; Memorial Sloan-Kettering Cancer Center; Monash University; Oregon Health and Science University","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Chemotherapy; Internal medicine; Docetaxel; Cancer; Androgen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.02304102603670297,"gpt":0.3423287589878519,"spread":0.3192877329511489,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001111575,0.000148434,0.0005787645,0.0003134371,0.00002523274,0.000006774735,0.00009506181,0.00003517074,0.0004062182],"category_scores_gemma":[0.0002324619,0.00008019953,0.00006282976,0.0002754265,0.0001105985,0.00008191096,0.00001014169,0.0003886346,0.00000380333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001415183,"about_ca_system_score_gemma":0.0003574314,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003221296,"about_ca_topic_score_gemma":0.0001921544,"domain_scores_codex":[0.9984846,0.00009082755,0.0004816702,0.0001255491,0.0005391091,0.0002782372],"domain_scores_gemma":[0.9990402,0.0001212888,0.0001987681,0.0001351166,0.0001742663,0.0003303405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.004407223,0.000151812,0.1496986,0.0001665946,0.0002584875,0.000509068,0.005582884,0.00004176082,0.005522937,0.0001035739,0.005899157,0.8276579],"study_design_scores_gemma":[0.4646691,0.01391325,0.2178174,0.00446817,0.0006028954,0.002013935,0.0007035211,0.0005938231,0.006851669,0.009493302,0.278557,0.0003159382],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9324593,0.006158862,0.000138274,0.0594875,0.0003575502,0.0003057703,0.000002079051,0.000009888612,0.001080766],"genre_scores_gemma":[0.989024,0.003529285,0.0005267477,0.001321959,0.002409773,0.000005954376,0.000006060229,0.00002463881,0.003151555],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8273419,"threshold_uncertainty_score":0.4447804,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137467802","doi":"10.1056/nejmoa1209096","title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2795,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre; Juravinski Cancer Centre; Université de Montréal","funders":"National Cancer Institute","keywords":"Prednisone; Medicine; Abiraterone acetate; Hazard ratio; Prostate cancer; Internal medicine; Interim analysis; Urology; Chemotherapy; Oncology; Surgery; Cancer; Gastroenterology; Androgen deprivation therapy; Randomized controlled trial; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.04024826831729372,"gpt":0.3675862686758338,"spread":0.3273380003585401,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001079698,0.0001618836,0.0006090594,0.0002623009,0.00002348301,0.000006306932,0.00007882987,0.00003526897,0.0005458939],"category_scores_gemma":[0.00009642054,0.00008681673,0.00005193342,0.0002496734,0.0001020406,0.0001670749,0.00001073209,0.0003733866,0.000005851561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001691256,"about_ca_system_score_gemma":0.0003231044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002472632,"about_ca_topic_score_gemma":0.00003893488,"domain_scores_codex":[0.9984131,0.00009022205,0.0004928823,0.00009991178,0.0005144312,0.0003893838],"domain_scores_gemma":[0.9989733,0.00007110155,0.0002162421,0.0001279253,0.000145282,0.0004661966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005891467,0.0003506425,0.5830376,0.0001955487,0.0003660975,0.000314694,0.009097696,0.0000104926,0.01111994,0.00001582909,0.005926242,0.3836737],"study_design_scores_gemma":[0.4009644,0.006747313,0.4149065,0.004063815,0.0008675337,0.003180525,0.0009681581,0.00006433832,0.01146233,0.0004972015,0.1559176,0.0003603471],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9416178,0.03862555,0.00005288528,0.01824871,0.0004476647,0.0004168722,0.000001949337,0.00000905887,0.0005794915],"genre_scores_gemma":[0.9807634,0.01207597,0.0005099134,0.0007108873,0.002686242,0.000009710972,0.000004789239,0.00002656107,0.003212577],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3950729,"threshold_uncertainty_score":0.5977156,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3176208875","doi":"10.1056/nejmoa2107322","title":"Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2598,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institute for Health and Care Research; Advanced Accelerator Applications; Endocyte; Novartis","keywords":"Prostate cancer; Medicine; Castration; Oncology; Cancer research; Prostate; Internal medicine; Cancer; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.0572078347326491,"gpt":0.3764620238311657,"spread":0.3192541890985165,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006810958,0.0001701164,0.0005958211,0.0001638753,0.00008404702,0.0000203533,0.0000792066,0.00003935598,0.0005808181],"category_scores_gemma":[0.0004817942,0.0001007627,0.0001257533,0.0002608521,0.0001051368,0.0001030988,0.00001433851,0.0002868343,0.000002568574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001492985,"about_ca_system_score_gemma":0.00177666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001284521,"about_ca_topic_score_gemma":0.0001739911,"domain_scores_codex":[0.9982235,0.00007380524,0.0005830132,0.0001769717,0.0006307294,0.000311961],"domain_scores_gemma":[0.9979311,0.0002696503,0.0002592431,0.0001673886,0.0009273618,0.0004452895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02275561,0.0006904523,0.009842715,0.001521074,0.002883047,0.008998377,0.008915393,0.0001523434,0.3362429,0.0005652925,0.1329751,0.4744577],"study_design_scores_gemma":[0.3007304,0.009423148,0.01358218,0.003497982,0.002874531,0.004714445,0.002487891,0.0001945216,0.05771734,0.002897258,0.6015024,0.0003778531],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.759486,0.06745282,0.001312498,0.1659512,0.002304139,0.001292967,0.0001024017,0.00003074817,0.002067325],"genre_scores_gemma":[0.9573889,0.009077273,0.004721647,0.001172279,0.006400142,0.00003671345,0.00009969737,0.00005142185,0.02105194],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4740798,"threshold_uncertainty_score":0.6359551,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3020771563","doi":"10.1056/nejmoa1911440","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2237,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; Janssen Biotech; Foundation Medicine; Pharmacyclics; Genentech; Astellas Pharma Europe; Tulane University; Eisai; Astellas Pharma; Merck Sharp and Dohme; Radboud Universitair Medisch Centrum; EMD Serono; Radboud Universiteit; AstraZeneca; Invitae; Massachusetts Medical Society; Bayer HealthCare; Sanofi; Exelixis; Pfizer; Northwestern University; Ipsen; Clovis Oncology; F. Hoffmann-La Roche; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Poly ADP ribose polymerase; Prostate cancer; Homologous recombination; PARP inhibitor; DNA repair; Cancer research; Polymerase; DNA Damage Repair; Medicine; Prostate; Gene; Oncology; Cancer; Biology; Internal medicine; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.08227651790290585,"gpt":0.3739222685155358,"spread":0.2916457506126299,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004162864,0.0001313189,0.0004886414,0.00009511055,0.0000522513,0.00001138301,0.00007697504,0.00002548299,0.0002960357],"category_scores_gemma":[0.0004103379,0.00007283769,0.00008588454,0.0001888404,0.00007932053,0.00008903853,0.000008679816,0.0002343505,0.000002530891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007335703,"about_ca_system_score_gemma":0.0007466218,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008663678,"about_ca_topic_score_gemma":0.00003091413,"domain_scores_codex":[0.998675,0.00003899773,0.0004658648,0.0001267355,0.0004729045,0.000220523],"domain_scores_gemma":[0.9985667,0.0001633908,0.0002236077,0.00007779164,0.000405309,0.0005631837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.05067164,0.0002861062,0.007623261,0.001394427,0.002001761,0.001985524,0.01479729,0.0001879697,0.3262759,0.000432626,0.1812562,0.4130873],"study_design_scores_gemma":[0.3731359,0.02525369,0.008925302,0.001714187,0.002405372,0.0008562497,0.001811981,0.0007323483,0.01720108,0.001336948,0.5663215,0.0003054785],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5912037,0.03076053,0.002250005,0.3717133,0.0009862743,0.001833488,0.0000788137,0.0000364898,0.001137433],"genre_scores_gemma":[0.9882951,0.001946536,0.001782116,0.001846438,0.004490231,0.00001537556,0.00002548278,0.00002387266,0.001574816],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4127818,"threshold_uncertainty_score":0.3241383,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2235405584","doi":"10.1056/nejmoa1506859","title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2187,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Stand Up To Cancer; Genentech; European Society for Medical Oncology; Cilag; Astellas Pharma; National Institute for Health and Care Research; Sanofi; Public Health Agency; Prostate Cancer UK; GlaxoSmithKline; Les Laboratories Pierre Fabre; Medical Research Council; Celgene; Bristol-Myers Squibb; Prostate Cancer Foundation; American Association for Cancer Research; AstraZeneca; Royal Marsden NHS Foundation Trust; Pfizer; Oncolytics Biotech; Cancer Research UK","keywords":"Olaparib; Poly ADP ribose polymerase; Prostate cancer; DNA repair; Polymerase; Cancer research; PARP inhibitor; Medicine; Internal medicine; Oncology; Prostate; DNA; Cancer; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.05424186371494471,"gpt":0.3566528702221747,"spread":0.30241100650723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001156601,0.0001333876,0.0005151398,0.0002927995,0.00002004552,0.000007145711,0.00005195883,0.00003237008,0.00006859132],"category_scores_gemma":[0.000421146,0.00007363456,0.00004422999,0.0002441592,0.0001251514,0.0001092118,0.00002039368,0.0003289156,0.000002254293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001473948,"about_ca_system_score_gemma":0.0007320739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003993051,"about_ca_topic_score_gemma":0.0002113579,"domain_scores_codex":[0.9986219,0.00009172338,0.0003894731,0.0001237926,0.0005293431,0.0002437412],"domain_scores_gemma":[0.998771,0.000124902,0.0001433644,0.00009828459,0.0002346229,0.0006277959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01202509,0.000310807,0.7300214,0.0004194395,0.0005626999,0.005972873,0.01389462,0.00006073396,0.006154537,0.0001033428,0.04444008,0.1860343],"study_design_scores_gemma":[0.6116978,0.01713216,0.1607473,0.005038647,0.001492088,0.005945974,0.003631531,0.0003849004,0.004157331,0.004158422,0.1851905,0.000423404],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9550505,0.03026172,0.00001158849,0.0132729,0.0003094406,0.0002643034,0.000002097233,0.00001164361,0.0008157841],"genre_scores_gemma":[0.9917576,0.004551125,0.0003951717,0.0004084885,0.001137605,0.000005514727,0.000004416986,0.00001598814,0.001724069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5996727,"threshold_uncertainty_score":0.300273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2620746860","doi":"10.1056/nejmoa1702900","title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1772,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Medical Research Council; Cardiff University; University of Glasgow; Swansea University; University of Sussex; King's College London; National Institute for Health and Care Research; University College London; Cancer Research UK; Royal Marsden NHS Foundation Trust","keywords":"Abiraterone acetate; Prostate cancer; Abiraterone; Androgen deprivation therapy; Medicine; Oncology; Internal medicine; Testosterone (patch); Cancer; Prostate; Hormone therapy; Prednisolone; Urology; Androgen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.05415089647709481,"gpt":0.3600978921108623,"spread":0.3059469956337675,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000594654,0.0001953311,0.0006177158,0.0001300317,0.000194485,0.00003523816,0.0001770886,0.00005590069,0.00009520195],"category_scores_gemma":[0.0001177938,0.00008998798,0.0000697558,0.00006235346,0.0002357963,0.0001555856,0.00001310858,0.0002533542,0.000001464286],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009970961,"about_ca_system_score_gemma":0.0004573909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004728906,"about_ca_topic_score_gemma":0.00006355879,"domain_scores_codex":[0.998624,0.00003148102,0.0003624539,0.0001650814,0.000484226,0.0003327493],"domain_scores_gemma":[0.9982366,0.00007771362,0.0004582248,0.0003053512,0.0005154284,0.0004066559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0823475,0.0002263191,0.07639642,0.0001325019,0.001108703,0.0008544637,0.002350021,0.000007243576,0.05721297,0.00001519516,0.01897469,0.760374],"study_design_scores_gemma":[0.5610922,0.04500264,0.1958002,0.002318674,0.0008561946,0.001350976,0.0001879343,0.00005692661,0.03128255,0.0001928047,0.1615614,0.0002974749],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9447792,0.01568943,0.00009927405,0.03780944,0.0001875411,0.0009505792,0.00001093985,0.0000138109,0.0004597766],"genre_scores_gemma":[0.9601531,0.02773739,0.0003371872,0.0003934994,0.003210735,0.00003317651,0.00001322207,0.00003660007,0.008085077],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7600765,"threshold_uncertainty_score":0.3669603,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141569270","doi":"10.1158/0008-5472.can-08-0249","title":"Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1412,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; Oregon National Primate Research Center; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; University of Washington; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Defense","keywords":"Prostate cancer; Castration; Androgen; Medicine; Prostate; Orchiectomy; Testosterone (patch); Internal medicine; Androgen deprivation therapy; Androgen receptor; CYP17A1; Cancer research; Cancer; Intracrine; Endocrinology; Oncology; Biology; Hormone; Gene; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.1079303838449509,"gpt":0.4065856309627567,"spread":0.2986552471178058,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007726069,0.0002059594,0.0005447837,0.0004845915,0.0002044911,0.0000209445,0.0001953268,0.00005105498,0.0001310898],"category_scores_gemma":[0.0002561127,0.0001604496,0.0001184163,0.001091745,0.0005051822,0.0001385565,0.00006182165,0.0004509552,0.000005585309],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007972522,"about_ca_system_score_gemma":0.003080731,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003865881,"about_ca_topic_score_gemma":0.001561196,"domain_scores_codex":[0.9970106,0.0001370003,0.0004776806,0.0005048498,0.0008831781,0.0009866196],"domain_scores_gemma":[0.9976214,0.0001747937,0.00009840602,0.0002974856,0.001539636,0.0002683119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02488648,0.00145332,0.06115043,0.005108962,0.000703886,0.003713796,0.006230886,0.00005473669,0.8585156,0.02316648,0.01161504,0.003400449],"study_design_scores_gemma":[0.02232222,0.004078224,0.02060137,0.002002453,0.0001380172,0.0002323465,0.002388519,0.0009333779,0.9349138,0.01052095,0.001302397,0.0005663025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989722,0.003130654,0.00003170719,0.003230499,0.0001018157,0.002999532,0.0004738109,0.00002437014,0.0002856589],"genre_scores_gemma":[0.9879718,0.004999121,0.0006963285,0.00009103821,0.0001004571,0.003437316,0.00004367505,0.00004959819,0.002610651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07639828,"threshold_uncertainty_score":0.6542946,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168108459","doi":"10.1016/s1470-2045(12)70379-0","title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1387,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"Janssen Research and Development; UCLH Biomedical Research Centre","keywords":"Abiraterone acetate; Medicine; Placebo; Prednisone; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Enzalutamide; Docetaxel; Population; Oncology; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.187337688920738,"gpt":0.4545089135261337,"spread":0.2671712246053957,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641254,0.0002592815,0.00215015,0.0001613824,0.0001578604,0.000013556,0.0001976042,0.0000566079,0.0001374977],"category_scores_gemma":[0.00005238489,0.0001173223,0.0004438003,0.0004423437,0.0002506557,0.00006796759,0.00003532356,0.0001037906,0.000001858205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004198121,"about_ca_system_score_gemma":0.0006199691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007652444,"about_ca_topic_score_gemma":0.001467372,"domain_scores_codex":[0.9974428,0.0006404388,0.0007126536,0.0002495397,0.0003933646,0.0005612333],"domain_scores_gemma":[0.9976661,0.0008552834,0.0005555762,0.0005318313,0.0002778269,0.0001134002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9420376,0.005636428,0.01478946,0.0001301817,0.01688264,0.0000145627,0.006387701,0.0005752128,0.01089463,0.0001125105,0.000158522,0.002380588],"study_design_scores_gemma":[0.9551365,0.00749364,0.008343978,0.00002556125,0.01875508,0.000005030901,0.001218721,0.0008365894,0.006760625,0.00003229629,0.001262072,0.000129909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837747,0.002015833,0.0000366939,0.002525269,0.0002579911,0.01071882,0.0003864799,0.00001464593,0.0002695927],"genre_scores_gemma":[0.992819,0.0007175906,0.0001205411,0.00005539147,0.0002155359,0.00391535,0.00009635864,0.00002131474,0.002038882],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01309893,"threshold_uncertainty_score":0.4784263,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2055346449","doi":"10.1016/s1470-2045(14)71205-7","title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1354,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Castration; Urology; Abiraterone; Enzalutamide; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1589090600127682,"gpt":0.4258998720708133,"spread":0.2669908120580451,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002998873,0.0005134636,0.003282598,0.0004817025,0.0001281249,0.00005791506,0.0003629067,0.0001271126,0.0001906786],"category_scores_gemma":[0.00009622835,0.0003006473,0.0002197622,0.001092295,0.0004041253,0.0001752098,0.00008584069,0.0005137865,0.000007720719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00176902,"about_ca_system_score_gemma":0.003078348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003552231,"about_ca_topic_score_gemma":0.01029028,"domain_scores_codex":[0.995339,0.001137285,0.0009978913,0.0006821157,0.000950179,0.0008935454],"domain_scores_gemma":[0.9970813,0.0007721098,0.0006680258,0.0007054448,0.0004818679,0.0002912504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9464379,0.002250246,0.002099341,0.0001144304,0.01489309,0.0004695777,0.0174573,0.01376485,0.001599766,0.00002648981,0.0003336929,0.0005533326],"study_design_scores_gemma":[0.9573971,0.01183193,0.001784175,0.00007425837,0.007183235,0.00001247772,0.005685242,0.01481517,0.0007373089,0.00002656291,0.0001560062,0.0002965203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799966,0.001235983,0.00007198528,0.003110346,0.0001606901,0.01328694,0.0001943093,0.00005556865,0.001887591],"genre_scores_gemma":[0.9910275,0.0005633815,0.0002729443,0.00008901483,0.0001833735,0.004745675,0.0001959956,0.0000579407,0.002864144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01177206,"threshold_uncertainty_score":0.9999446,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2792086148","doi":"10.1056/nejmoa1715546","title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1326,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Thomas Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Ipsen; Sanofi; Astellas Pharma; Clovis Oncology; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Prostate cancer; Cancer; Metastasis; Oncology; Medicine; Prostate; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04574914809190925,"gpt":0.3578084877900213,"spread":0.3120593396981121,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007292946,0.0001654179,0.000579927,0.000300011,0.00004186261,0.000008911053,0.00008420838,0.00003612154,0.0002748027],"category_scores_gemma":[0.0002056626,0.00008644672,0.00004606149,0.0002372971,0.0002681118,0.00008213543,0.00002697122,0.0002031764,0.00000243696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002100698,"about_ca_system_score_gemma":0.0004260024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001106703,"about_ca_topic_score_gemma":0.001075907,"domain_scores_codex":[0.9986588,0.00008774192,0.0004098275,0.0001545579,0.000411151,0.0002779647],"domain_scores_gemma":[0.9989418,0.0001324516,0.0001467933,0.0001787504,0.0002137707,0.0003864545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01022123,0.0002476432,0.2900306,0.00009096496,0.0006184828,0.001502947,0.006234938,0.000003758565,0.006604133,0.0000871288,0.005564807,0.6787934],"study_design_scores_gemma":[0.4967702,0.03109623,0.226253,0.002301797,0.001235435,0.002672011,0.001682349,0.00008772193,0.01077562,0.002801046,0.2239887,0.0003359069],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9530934,0.01557634,0.00001551703,0.02898217,0.0005043792,0.0002891776,0.000009140934,0.000007727855,0.001522144],"genre_scores_gemma":[0.9772782,0.01536233,0.0003125813,0.0002271909,0.003927432,0.000006274006,0.000004841762,0.00001896641,0.00286222],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6784575,"threshold_uncertainty_score":0.3525195,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2156306108","doi":"10.1016/j.juro.2008.11.032","title":"Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial","year":2009,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1228,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Prostate cancer; Prostatectomy; Randomized controlled trial; Oncology; Internal medicine; Metastasis; Adjuvant; Clinical endpoint; Cancer; Urology; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.06022286967598006,"gpt":0.4160290638458764,"spread":0.3558061941698963,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007598413,0.0001564666,0.001788061,0.0001237354,0.00004990185,0.000006205214,0.0001548672,0.0001161782,0.00002285311],"category_scores_gemma":[0.001102782,0.00007023874,0.0005266136,0.00009439781,0.0007978071,0.00004740556,0.00001527678,0.0003389748,8.45297e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001911749,"about_ca_system_score_gemma":0.0002913308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000169288,"about_ca_topic_score_gemma":0.000006346097,"domain_scores_codex":[0.996272,0.001832556,0.001223285,0.0001532114,0.0002689894,0.000250002],"domain_scores_gemma":[0.9949722,0.003171525,0.001246479,0.0001655855,0.0003264724,0.0001177734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.889977,0.0006197662,0.004478684,0.00003561504,0.001502693,0.00004701331,0.000529582,0.000006207837,0.03155503,0.00001656258,0.00009065753,0.07114114],"study_design_scores_gemma":[0.8902229,0.05045899,0.04393138,0.00007412115,0.004366478,0.0001664532,0.0001734433,0.0001191254,0.008880833,0.001388626,0.00009547151,0.0001221665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9607042,0.03367479,0.0003631806,0.003054451,0.0003236812,0.001800381,0.00006529447,0.000004844968,0.000009181485],"genre_scores_gemma":[0.9356233,0.06338059,0.0004608051,0.0001119112,0.0003168088,0.00002529526,0.000003791196,0.00001149457,0.0000659824],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07101897,"threshold_uncertainty_score":0.2939554,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165542862","doi":"10.1200/jco.2007.12.4008","title":"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1145,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prednisone; Prostate cancer; Internal medicine; Urology; Survival analysis; Surgery; Oncology; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.2067678927162186,"gpt":0.5167604900016837,"spread":0.309992597285465,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004571894,0.0002888795,0.002362962,0.0002004199,0.0001818048,0.00001843408,0.0004612457,0.0003201059,0.0001274701],"category_scores_gemma":[0.002215875,0.0001477644,0.0004292662,0.0004862683,0.0004479719,0.00021415,0.00009236702,0.001409863,0.000008555526],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007896245,"about_ca_system_score_gemma":0.007858319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001727697,"about_ca_topic_score_gemma":0.001064004,"domain_scores_codex":[0.9942851,0.00099088,0.002722342,0.0004144565,0.0008996059,0.0006875964],"domain_scores_gemma":[0.9942452,0.002771704,0.001420877,0.0003801434,0.0007916718,0.0003903717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4987577,0.02397811,0.2909245,0.0002699508,0.003449678,0.01324713,0.009835739,0.0009790984,0.0006565691,0.00003900536,0.04414036,0.1137222],"study_design_scores_gemma":[0.2911211,0.1226603,0.4361692,0.0003454549,0.00137869,0.001181977,0.008484102,0.001127798,0.000307253,0.0001977771,0.136551,0.0004754077],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.974713,0.002708249,0.00006985968,0.0170017,0.001462082,0.003599242,0.00006639762,0.0000181533,0.000361289],"genre_scores_gemma":[0.9814227,0.008455556,0.001385774,0.0007712009,0.001422002,0.0003069889,0.00002322704,0.0000428373,0.006169746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2076366,"threshold_uncertainty_score":0.9977662,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205918537","doi":"10.1038/s41572-020-00243-0","title":"Prostate cancer","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Disease Primers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1109,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Prostate cancer; Medicine; Prostatectomy; Oncology; Cancer; Internal medicine; Radiation therapy; Androgen deprivation therapy; Olaparib; PTEN; Cancer research; Biology; PI3K/AKT/mTOR pathway","retraction":null,"screen_n_in":null,"score":{"opus":0.06710718438827394,"gpt":0.4623833379955043,"spread":0.3952761536072303,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035422,0.0008022293,0.00393091,0.0002571766,0.000107712,0.00006109505,0.0002690853,0.0006385067,0.00112408],"category_scores_gemma":[0.0003085764,0.0004848679,0.002213688,0.00105004,0.0001216465,0.00007818627,0.0001576476,0.002189604,0.0003465989],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007905436,"about_ca_system_score_gemma":0.004874509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007295521,"about_ca_topic_score_gemma":0.000001365823,"domain_scores_codex":[0.996468,0.0003982287,0.0008072451,0.001022653,0.0006458768,0.0006580157],"domain_scores_gemma":[0.9972242,0.00007565237,0.0003940773,0.001046766,0.0002228671,0.001036446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004246012,0.0001444729,0.00003534856,0.09679291,0.00066699,0.0005082004,0.00001079859,1.462625e-8,1.757573e-7,0.000029053,0.03166218,0.8701074],"study_design_scores_gemma":[0.0004683487,0.00002789587,0.00001444401,0.1077377,0.007791856,0.00002367817,0.000002678051,2.627966e-7,0.000001018737,0.000003942584,0.8835352,0.0003929017],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[4.657927e-7,0.9912918,3.812989e-7,0.0005500575,0.000573674,0.006060659,0.0003388161,0.00007504794,0.001109155],"genre_scores_gemma":[2.452958e-7,0.9804385,0.0001660415,0.000534172,0.0005896186,0.00246154,0.002398693,0.0001393253,0.01327188],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8697145,"threshold_uncertainty_score":0.999789,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130955565","doi":"10.1158/2159-8290.cd-11-0130","title":"Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets","year":2011,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1020,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Weill Cornell Medical College; U.S. Public Health Service","keywords":"Prostate cancer; Cancer research; Prostate; Biology; Aurora kinase; Cancer; Adenocarcinoma; Neuroendocrine tumors; In vivo; Medicine; Internal medicine; Cell cycle; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02261109907375157,"gpt":0.2972642332103163,"spread":0.2746531341365647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004080419,0.0001010242,0.0002148615,0.00008736309,0.00001917352,0.000009202835,0.00005113162,0.00001491006,0.00006280431],"category_scores_gemma":[0.00001013615,0.00008137622,0.00004413486,0.0001650576,0.00009705003,0.0002583021,0.00003509066,0.0000616675,8.230061e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004925454,"about_ca_system_score_gemma":0.0002734854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007780542,"about_ca_topic_score_gemma":0.00001659747,"domain_scores_codex":[0.9991857,0.00001568619,0.0002584368,0.0002055864,0.0001828676,0.0001516625],"domain_scores_gemma":[0.9994573,0.000005258906,0.0001727297,0.0001776395,0.0001067239,0.00008036607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007469438,0.000101932,0.09995928,0.0004775677,0.0001148067,0.00002117429,0.00123283,0.000003160588,0.8821467,0.000135585,0.0001237255,0.01493634],"study_design_scores_gemma":[0.0009679921,0.00006975752,0.2669307,0.0001370817,0.00008843127,0.000002528262,0.00004153058,0.00003482374,0.7313556,0.00009924382,0.000216506,0.0000557849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993928,0.004433205,0.0001273411,0.0006054658,0.0001575297,0.0004833803,0.0001449407,0.00001106088,0.0001090681],"genre_scores_gemma":[0.9857869,0.009285321,0.00002173884,0.00005962101,0.00004491918,0.00007668859,0.00007924643,0.00001900366,0.004626545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1669714,"threshold_uncertainty_score":0.3318426,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4211087830","doi":"10.1016/s0140-6736(14)61947-4","title":"Prostate cancer","year":2015,"lang":"en","type":"review","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":917,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Astellas Pharma; National Cancer Institute; Cancer Research UK; Prostate Cancer UK; Ipsen; National Institute for Health and Care Research; GlaxoSmithKline","keywords":"Prostate cancer; Overdiagnosis; Medicine; Docetaxel; Oncology; Internal medicine; Disease; Cancer; Prostate; Cabazitaxel; Androgen deprivation therapy","retraction":null,"screen_n_in":null,"score":{"opus":0.2293748849616526,"gpt":0.4760491146759444,"spread":0.2466742297142918,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003791137,0.0002298409,0.001717554,0.00005294307,0.00005556182,0.00003024759,0.0002672509,0.0001096155,0.0001825362],"category_scores_gemma":[0.00002400965,0.0000957528,0.0001911782,0.0002527949,0.000105219,0.0000212832,0.00008929108,0.0005004391,0.0004109609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002780289,"about_ca_system_score_gemma":0.001084921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004895795,"about_ca_topic_score_gemma":0.000006251619,"domain_scores_codex":[0.9987826,0.00009433265,0.0001971011,0.000221986,0.0003131581,0.0003907644],"domain_scores_gemma":[0.998981,0.00004424834,0.00009744656,0.0006647145,0.00008953039,0.0001230888],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006717881,0.00001713395,0.00002825488,0.008610863,0.0002492388,0.00004496366,0.00008158817,4.116633e-8,6.646265e-8,0.00002462521,0.1784929,0.8123831],"study_design_scores_gemma":[0.0009005413,0.00006652572,0.000008464983,0.007943667,0.0008324936,0.0000446093,0.000008368582,7.669243e-7,6.741971e-7,0.00006573752,0.9900197,0.0001084893],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000003478008,0.9844163,1.293617e-7,0.002526843,0.0002216679,0.001405532,0.0002135864,0.00006332841,0.01114915],"genre_scores_gemma":[9.946641e-7,0.9618892,0.00002018719,0.0001911768,0.002285727,0.000574117,0.0001842838,0.00004605993,0.03480825],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8122746,"threshold_uncertainty_score":0.5282208,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2938589827","doi":"10.1016/s1470-2045(19)30082-8","title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":813,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Internal medicine; Oncology; Androgen deprivation therapy; Urology; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.06476036434540433,"gpt":0.3773706945959527,"spread":0.3126103302505484,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009434748,0.000260711,0.001760322,0.0003014013,0.00006573943,0.00002280219,0.0001419694,0.00008652164,0.0001946413],"category_scores_gemma":[0.00004726383,0.0001490413,0.0001417602,0.0007481099,0.0002141528,0.0001276907,0.00004863909,0.0003843154,0.00001178648],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000467002,"about_ca_system_score_gemma":0.0008388882,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003810683,"about_ca_topic_score_gemma":0.005581571,"domain_scores_codex":[0.9973656,0.0006291393,0.0005761815,0.0004109451,0.0005067752,0.0005113538],"domain_scores_gemma":[0.9981218,0.0005653754,0.0004859494,0.0004135337,0.0003065402,0.00010681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8935666,0.001352762,0.08673543,0.00007707863,0.004656103,0.0001026106,0.002619773,0.008883883,0.0001861742,0.00004618794,0.00004904062,0.001724345],"study_design_scores_gemma":[0.861499,0.006639343,0.1262909,0.00005852488,0.003176355,0.000001340856,0.0001669464,0.001604876,0.0003378991,0.00002228095,0.00005545255,0.0001471247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919254,0.0001526784,0.00005679205,0.0009216665,0.0002191808,0.006174786,0.0003699321,0.00001993979,0.0001596665],"genre_scores_gemma":[0.9971771,0.0004753007,0.00031586,0.00009953722,0.0001271118,0.000636387,0.0005758891,0.00002493753,0.0005678997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03955542,"threshold_uncertainty_score":0.6077729,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3087416729","doi":"10.1056/nejmoa2022485","title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":766,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Daiichi Sankyo Europe; Pharmacyclics; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; Sierra Oncology; Bavarian Nordic; Astellas Pharma; Eisai; Celldex Therapeutics; Daiichi-Sankyo; Clovis Oncology; National Institute for Health and Care Research; AstraZeneca; Invitae; Ipsen; Vertex Pharmaceuticals; Boston Scientific Corporation; Endocyte; NRG Oncology; F. Hoffmann-La Roche; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Prostate cancer; Oncology; Medicine; Internal medicine; Cancer research; Cancer; Biology; Poly ADP ribose polymerase","retraction":null,"screen_n_in":null,"score":{"opus":0.06052038105550388,"gpt":0.343200598017492,"spread":0.2826802169619881,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004629795,0.0001395638,0.0005330411,0.0001404356,0.00002713943,0.00001011545,0.00007294373,0.00002278436,0.0002925131],"category_scores_gemma":[0.000162484,0.00007176455,0.00003617167,0.000375584,0.00009950253,0.00009909861,0.000009278901,0.0003915358,0.000002315568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009588481,"about_ca_system_score_gemma":0.000906772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004632431,"about_ca_topic_score_gemma":0.000495987,"domain_scores_codex":[0.9984633,0.00007884821,0.0004392337,0.0001334051,0.0006591092,0.0002260954],"domain_scores_gemma":[0.9989265,0.0001103692,0.0001846889,0.00007938533,0.0002258442,0.000473225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1133342,0.0006231216,0.4448446,0.001242507,0.002033114,0.02567574,0.03468267,0.001046484,0.1026893,0.0003385417,0.01812837,0.2553613],"study_design_scores_gemma":[0.6512006,0.03602867,0.1969521,0.004987217,0.001725541,0.001925419,0.006239423,0.0005716835,0.007868824,0.0004887402,0.09146899,0.0005427431],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8891492,0.006396201,0.0001097314,0.1027913,0.0001954304,0.0003924016,0.000008500361,0.00000979884,0.0009473976],"genre_scores_gemma":[0.9955412,0.001462893,0.0004333335,0.0005807184,0.001399819,0.000004834671,0.00001002707,0.00001733471,0.0005498229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5378664,"threshold_uncertainty_score":0.3202814,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2884001931","doi":"10.1016/j.cell.2018.06.039","title":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":748,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"V Foundation for Cancer Research; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Movember Foundation; Howard Hughes Medical Institute; Stand Up To Cancer; U.S. Department of Defense","keywords":"Biology; Chromothripsis; Prostate cancer; Chromoplexy; Carcinogenesis; Transcriptome; Genome instability; Genetics; Androgen receptor; Copy-number variation; Tandem exon duplication; Gene duplication; Cancer research; Structural variation; Exome; Epigenetics; Cancer; Genome; Exome sequencing; Mutation; Gene; DNA damage; DNA; Gene expression; PCA3","retraction":null,"screen_n_in":null,"score":{"opus":0.02002256703857838,"gpt":0.3144128739964921,"spread":0.2943903069579138,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007751948,0.00006629062,0.0001088005,0.00006569085,0.00003602588,0.00001399208,0.00002329016,0.00002074832,0.000236647],"category_scores_gemma":[0.000006115478,0.00004772489,0.00001225181,0.00008663008,0.00006935006,0.00004610753,0.0000214514,0.00007354695,0.00001809501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001038911,"about_ca_system_score_gemma":0.0001102927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003939284,"about_ca_topic_score_gemma":0.0001364921,"domain_scores_codex":[0.9994877,0.0000202906,0.00009210256,0.0001488713,0.0000835582,0.0001674677],"domain_scores_gemma":[0.9997745,0.00001432021,0.00002385139,0.00008255784,0.00004281545,0.00006194328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.00208678,0.0001493354,0.4585385,0.0007205263,0.0001691677,0.0001871745,0.01517148,0.00001858423,0.4877939,0.00007774063,0.001312728,0.03377415],"study_design_scores_gemma":[0.004438748,0.0003510168,0.9685153,0.00005347934,0.00006404487,0.00001064875,0.0001322723,0.002553163,0.02178297,0.0005349539,0.001456132,0.0001072343],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952372,0.001912078,0.000006651145,0.0004983483,0.0000873403,0.0003645189,0.000009092135,0.000009962049,0.001874821],"genre_scores_gemma":[0.9953925,0.0004688233,0.0003476795,0.00008981803,0.0000804802,0.00002985855,0.00001434906,0.000009693213,0.003566771],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5099769,"threshold_uncertainty_score":0.2591119,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142466432","doi":"10.1016/s1470-2045(12)70560-0","title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":740,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Institut National Du Cancer; Sanofi; Roche; Bayer; AstraZeneca; Unicancer; Novartis; Pfizer; Amgen","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Estramustine; Clinical endpoint; Chemotherapy; Goserelin; Prostate-specific antigen; Urology; Cancer; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.14905012062049,"gpt":0.4450497540010663,"spread":0.2959996333805763,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192904,0.0002656344,0.001118867,0.0001191281,0.0001286014,0.000092088,0.0003521029,0.00008572644,0.0008715917],"category_scores_gemma":[0.00006730586,0.0001224624,0.00003973714,0.0004975838,0.000262637,0.0002598334,0.00008246191,0.0004094558,0.00007312008],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002924768,"about_ca_system_score_gemma":0.001160226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001217665,"about_ca_topic_score_gemma":0.0007363964,"domain_scores_codex":[0.9977265,0.0004435072,0.0004713348,0.0003990828,0.0003003402,0.0006592151],"domain_scores_gemma":[0.9986374,0.0003519807,0.0002419678,0.0004425977,0.0001776552,0.0001483866],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9152576,0.002894945,0.001380214,0.00008777365,0.0006759848,0.0004085925,0.001869453,0.00001179327,0.01047804,0.0000283028,0.006630282,0.06027706],"study_design_scores_gemma":[0.9724851,0.01226028,0.001404367,0.0001264652,0.0001550631,0.00009701401,0.0003003701,0.0005111106,0.003600303,0.000350141,0.00850944,0.0002003795],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9677089,0.001382793,0.00002718341,0.01783268,0.0001481806,0.01155978,0.00003891664,0.00003492833,0.00126659],"genre_scores_gemma":[0.9728683,0.008064532,0.0013035,0.002623817,0.000510479,0.009630096,0.0001094319,0.00005772603,0.004832138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06007668,"threshold_uncertainty_score":0.9543318,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2167749314","doi":"10.1158/0008-5472.can-07-5997","title":"Androgen Levels Increase by Intratumoral <i>De novo</i> Steroidogenesis during Progression of Castration-Resistant Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":739,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Dihydrotestosterone; Androgen; Androgen receptor; LNCaP; Androgen deprivation therapy; Tumor progression; Internal medicine; Endocrinology; Cancer research; Cancer; Prostate; Medicine; Biology; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.08711475349095844,"gpt":0.4118222421841693,"spread":0.3247074886932109,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006011658,0.0002297902,0.0004177061,0.0002756432,0.0004676146,0.00003627912,0.0002146065,0.0001214447,0.0004927691],"category_scores_gemma":[0.00007100811,0.0001794857,0.00009464131,0.0008509376,0.0006791263,0.0001805663,0.0001293531,0.0004983478,0.00001051287],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009241637,"about_ca_system_score_gemma":0.002689094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00218264,"about_ca_topic_score_gemma":0.0002061956,"domain_scores_codex":[0.9965648,0.0002279616,0.0004050769,0.0005176776,0.001294488,0.0009899861],"domain_scores_gemma":[0.9981347,0.00007195588,0.00009889453,0.0003983988,0.0007841451,0.0005119398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004876041,0.0003280243,0.1028136,0.0006863094,0.0001458967,0.0006835712,0.001035855,0.000009480846,0.8818322,0.000006527819,0.003980074,0.003602368],"study_design_scores_gemma":[0.004582967,0.0006654491,0.04135608,0.0006589993,0.00004175754,0.0001258608,0.0002217818,0.00001955232,0.9504408,0.00001774404,0.001676506,0.0001924583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807967,0.01542784,0.000001638268,0.001339759,0.00005875536,0.001391718,0.0005796956,0.00004385736,0.0003600609],"genre_scores_gemma":[0.986662,0.006402055,0.0001071244,0.00004263664,0.0001999131,0.001080367,0.00006646533,0.00005810905,0.0053813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06860857,"threshold_uncertainty_score":0.7319213,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121518362","doi":"10.1002/cncr.20408","title":"Human prostate cancer risk factors","year":2004,"lang":"en","type":"review","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Centre for Disease Control","funders":"U.S. Environmental Protection Agency","keywords":"Prostate cancer; Medicine; Cancer; Carcinogenesis; Disease; Epidemiology; Prostate; Risk factor; Oncology; Bioinformatics; Internal medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1032435243626195,"gpt":0.4560787160261041,"spread":0.3528351916634846,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001130859,0.0006442804,0.001936874,0.000264831,0.0002360098,0.00004793163,0.0002158435,0.0003777801,0.001997127],"category_scores_gemma":[0.00002032865,0.0003969585,0.0006823755,0.000501702,0.0001997714,0.00007101849,0.0000870741,0.001014215,0.0001166187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002756918,"about_ca_system_score_gemma":0.003305763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002994049,"about_ca_topic_score_gemma":0.0001343577,"domain_scores_codex":[0.9975245,0.00007975348,0.0005029359,0.0007177884,0.0004685294,0.0007065082],"domain_scores_gemma":[0.9985332,0.00003538356,0.0003566555,0.0005509474,0.0001477291,0.0003761066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003129695,0.0001209625,0.002303349,0.04210641,0.001533376,0.0001500492,0.0003229513,0.000004256724,0.000002600007,0.00002144112,0.004529968,0.9488733],"study_design_scores_gemma":[0.001208243,0.0001493206,0.0003004886,0.03793805,0.002857752,0.000008203238,0.00002064714,2.095727e-7,0.0000288439,0.00003494424,0.9570499,0.0004033909],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000461382,0.99401,3.704934e-7,0.00008305081,0.0005976444,0.002455394,0.001183321,0.0001203441,0.001088534],"genre_scores_gemma":[0.00007057688,0.9665221,0.00001297721,0.00003021294,0.0006575233,0.001937915,0.0004437706,0.0001632951,0.03016164],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.95252,"threshold_uncertainty_score":0.9998482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2989894179","doi":"10.1016/s1470-2045(19)30684-9","title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Prostate Cancer UK; Public Health Agency; Division of Research, Evaluation, and Communication; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Medical Research Council; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; U.S. Department of Veterans Affairs","keywords":"Olaparib; Medicine; Prostate cancer; Open label; Oncology; Internal medicine; Urology; Cancer; Randomized controlled trial; Gene; Biology; Poly ADP ribose polymerase; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.06985848620486315,"gpt":0.3983035503391584,"spread":0.3284450641342952,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006505047,0.0002200703,0.0008185846,0.00009072928,0.0001439192,0.00004782209,0.0002112606,0.00005817339,0.0002245753],"category_scores_gemma":[0.0000498832,0.0001109792,0.0000323108,0.0003338486,0.0001579103,0.000176068,0.0000611533,0.0003144973,0.00003302783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004377957,"about_ca_system_score_gemma":0.001497502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003280822,"about_ca_topic_score_gemma":0.002995463,"domain_scores_codex":[0.99797,0.0003565329,0.0004101352,0.0003971546,0.0003486841,0.0005175379],"domain_scores_gemma":[0.998748,0.0002026843,0.0002208184,0.0004906395,0.0002119953,0.0001258563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9596585,0.005033165,0.0270315,0.0001136391,0.0007090644,0.000144308,0.002624221,0.00008611616,0.001398922,0.00004545961,0.00112815,0.00202693],"study_design_scores_gemma":[0.964244,0.0114346,0.01519254,0.0001410509,0.0003702222,0.000008330198,0.0002920953,0.0004464103,0.0007590284,0.00001536897,0.006911413,0.0001849488],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857726,0.0003149389,0.000005262122,0.002262568,0.0001429689,0.01005902,0.00009013608,0.00004278644,0.001309749],"genre_scores_gemma":[0.9915929,0.0001353357,0.001957831,0.0005485338,0.0001510195,0.002267541,0.000337105,0.00003710777,0.002972645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01183896,"threshold_uncertainty_score":0.45256,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2664930764","doi":"10.1016/j.eururo.2017.06.002","title":"Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Medical Research Council; Sanofi Genzyme; Astellas Pharma; National Institute for Health and Care Research; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Bristol-Myers Squibb; Swiss Cancer Research Foundation; Sanofi; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Amgen; European School of Oncology; National Health and Medical Research Council; Cancer Research UK","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Management of prostate cancer; Consensus conference; Prostate disease; Oncology; Gynecology; General surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02343196803911439,"gpt":0.3142505546983205,"spread":0.2908185866592061,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003225611,0.0002212055,0.0003777632,0.00004146436,0.0003250057,0.00001840266,0.0005014164,0.00003129313,0.00005321945],"category_scores_gemma":[0.00006654482,0.0001085069,0.00007576819,0.00009587656,0.001227433,0.00005865966,0.0003503226,0.000263358,0.000006332412],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005611609,"about_ca_system_score_gemma":0.0002552041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000127618,"about_ca_topic_score_gemma":0.00007352907,"domain_scores_codex":[0.9981556,0.0001853863,0.0004172829,0.0004261102,0.0004031782,0.0004124707],"domain_scores_gemma":[0.997105,0.00004261402,0.0008664835,0.001375601,0.0005226653,0.00008760652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01245604,0.0004801582,0.8637376,0.0006392959,0.001151465,0.001857238,0.001957321,0.0003920986,0.00196452,0.0003245589,0.002071234,0.1129685],"study_design_scores_gemma":[0.00713989,0.0008862444,0.9602911,0.0003083692,0.0002693191,0.00002960377,0.0001498051,0.00002237054,0.002308517,0.00004286021,0.02840417,0.0001477293],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9717951,0.001469433,0.000002900492,0.007928038,0.0003814503,0.002166274,0.0001604869,0.00002211276,0.01607417],"genre_scores_gemma":[0.9868783,0.002189267,0.0001161039,0.0001520892,0.00003156881,0.0001358091,0.00002590325,0.00004098523,0.01042998],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1128207,"threshold_uncertainty_score":0.4522527,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2567987817","doi":"10.1038/nature20788","title":"Genomic hallmarks of localized, non-indolent prostate cancer","year":2017,"lang":"en","type":"article","venue":"Nature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Université Laval; Centre hospitalier de l'Université Laval; University Health Network; Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Simon Fraser University; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Biology; Prostate; DNA methylation; Chromoplexy; Exome; Disease; Exome sequencing; Gene; Genetics; Cancer research; Computational biology; Cancer; Medicine; Pathology; Mutation; PCA3; Gene expression","retraction":null,"screen_n_in":null,"score":{"opus":0.01502225993071806,"gpt":0.3512631387959511,"spread":0.336240878865233,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001114013,0.0001127082,0.0002548305,0.00005759411,0.0001306575,0.00002396794,0.000180695,0.0004548452,0.0001777275],"category_scores_gemma":[0.00003868473,0.00007583019,0.00008856253,0.00003927341,0.0001418306,0.0000566305,0.00008659349,0.001014473,0.00001681746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001249123,"about_ca_system_score_gemma":0.0002880802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002565027,"about_ca_topic_score_gemma":0.00006449735,"domain_scores_codex":[0.9991391,0.00001010109,0.0001301904,0.0002042915,0.0002766218,0.0002397333],"domain_scores_gemma":[0.9991116,0.00001118696,0.0001110914,0.0004949927,0.0001592911,0.0001118665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005634219,0.0004448384,0.7451793,0.001205879,0.0007435299,0.0004545612,0.001425826,0.00001454956,0.08949582,0.0001602993,0.03887145,0.1163697],"study_design_scores_gemma":[0.01118591,0.0004380944,0.7823639,0.0007801024,0.0001771855,0.00002062323,0.00009634581,0.0002458632,0.1180423,0.0001622068,0.08625975,0.0002277112],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.967677,0.01306658,0.000003626634,0.006840401,0.0004046824,0.000745756,0.00007339561,0.00001768174,0.0111709],"genre_scores_gemma":[0.9864109,0.002909206,0.0001323593,0.000290507,0.0001871299,0.00004841828,0.00002627826,0.00001915515,0.009976109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.116142,"threshold_uncertainty_score":0.4407436,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2049161486","doi":"10.1111/j.1464-410x.2008.08183.x","title":"The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer","year":2008,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":614,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Surrey Memorial Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Urology; Testosterone (patch); Androgen deprivation therapy; Hormone antagonist; Clinical endpoint; Randomized controlled trial; Population; Prostate; Dosing; Prostate-specific antigen; Cancer; Internal medicine; Hormone; Endocrine system","retraction":null,"screen_n_in":null,"score":{"opus":0.03535916653170147,"gpt":0.3437018922021902,"spread":0.3083427256704888,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007567839,0.0001323362,0.0009944133,0.00009332511,0.0001873947,0.00002685639,0.0001782056,0.00004535419,0.0000234979],"category_scores_gemma":[0.00008685319,0.00008115692,0.00004050221,0.0001476217,0.0006312709,0.0001347783,0.00008210012,0.0003887518,3.498517e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005591491,"about_ca_system_score_gemma":0.0002557913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006447578,"about_ca_topic_score_gemma":0.001063965,"domain_scores_codex":[0.9980657,0.0004617117,0.0006872739,0.0001753674,0.0003308143,0.0002791084],"domain_scores_gemma":[0.99863,0.0003882652,0.0003933811,0.0001124135,0.0003424257,0.0001334544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8011584,0.004823462,0.175946,0.00001398231,0.0007029411,0.001283479,0.001810697,0.00003705348,0.00001216943,0.000004881203,0.0005466504,0.01366023],"study_design_scores_gemma":[0.6593872,0.0102631,0.3288372,0.000121401,0.0001617375,0.0004745362,0.0001742431,0.0000321898,0.000005327041,0.00001312391,0.0004629469,0.00006694581],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837391,0.01258367,0.00001363704,0.0004592784,0.0000635539,0.0029418,0.00001768808,0.000002776606,0.0001784915],"genre_scores_gemma":[0.9873484,0.01217641,0.0001030568,0.00007304133,0.00002896083,0.00008343114,0.000008723601,0.00001239934,0.0001655111],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1528912,"threshold_uncertainty_score":0.3309483,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1588197864","doi":"10.1002/pros.22742","title":"Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis","year":2013,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Lymph; Thorax (insect anatomy); Metastasis; Population; Cohort; Bone metastasis; Cancer; Prostate; Pathology; Internal medicine; Oncology; Anatomy","retraction":null,"screen_n_in":null,"score":{"opus":0.01533274219245804,"gpt":0.2925605081949433,"spread":0.2772277660024852,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000163423,0.0001321682,0.0003173001,0.000176075,0.0000617214,0.00002240226,0.00006907535,0.00001859603,0.0001335888],"category_scores_gemma":[0.00002701229,0.00006782928,0.00006984031,0.001265871,0.00009014207,0.0001229844,0.00002282231,0.0001127516,0.000009826295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001623103,"about_ca_system_score_gemma":0.0001081891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003264516,"about_ca_topic_score_gemma":0.0002953629,"domain_scores_codex":[0.9988198,0.00007560825,0.0002668501,0.000190338,0.0003712073,0.0002761707],"domain_scores_gemma":[0.9991936,0.00005360121,0.0001366346,0.0002608387,0.0002834641,0.00007185933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001096575,0.0002434187,0.9942141,0.00009976057,0.0003933492,0.000002199135,0.0003699617,0.0009339958,0.00009583505,0.00000847157,0.00005974999,0.002482548],"study_design_scores_gemma":[0.003485392,0.000355998,0.9918649,0.00007363429,0.0005453788,1.590989e-7,0.00006265349,0.002497225,0.0008849623,0.0001273219,0.00002162504,0.00008076279],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960366,0.0002257451,0.00003172136,0.001486071,0.00001002263,0.001903313,0.0002596335,0.00001925947,0.00002766465],"genre_scores_gemma":[0.9970499,0.00004780256,0.000133696,0.00005119803,0.000005462191,0.0003794119,0.001896324,0.00001348964,0.0004227228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002969153,"threshold_uncertainty_score":0.4934994,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2131456094","doi":"10.1158/0008-5472.can-08-3667","title":"Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":532,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"TMPRSS2; Prostate cancer; Erg; Abiraterone acetate; Cancer research; PTEN; LNCaP; Androgen receptor; Docetaxel; Prostate; Androgen deprivation therapy; Medicine; Cancer; Biology; Oncology; Internal medicine; PI3K/AKT/mTOR pathway; Apoptosis","retraction":null,"screen_n_in":null,"score":{"opus":0.02910325348655226,"gpt":0.3281111560618453,"spread":0.2990079025752931,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002828871,0.000194122,0.0003750458,0.0002609289,0.000127372,0.00005568347,0.00009062673,0.00006432542,0.00009888022],"category_scores_gemma":[0.00002532772,0.0001488188,0.0000306705,0.0007597456,0.0002084647,0.0002206582,0.00004234458,0.0003817241,0.000002401611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004660441,"about_ca_system_score_gemma":0.0009216341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003666734,"about_ca_topic_score_gemma":0.0006989327,"domain_scores_codex":[0.9973675,0.0001192217,0.0003744507,0.0004963842,0.0009410545,0.0007014046],"domain_scores_gemma":[0.9986138,0.00007047787,0.0001246331,0.0002731736,0.0006556634,0.0002621927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.002526679,0.0002294282,0.1780455,0.0001307601,0.00004430435,0.00006822932,0.0009558019,0.00002189868,0.8094915,0.00000791452,0.00005851144,0.008419459],"study_design_scores_gemma":[0.005841815,0.000688378,0.5497575,0.0006790209,0.00003170984,0.000001056944,0.0001413555,0.00008241367,0.4419566,0.00004330831,0.0006087952,0.0001680793],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950446,0.00165977,0.000003748093,0.0006016276,0.000052938,0.001555829,0.00087119,0.00001865339,0.0001916261],"genre_scores_gemma":[0.9965342,0.002142559,0.0001089723,0.0001580982,0.00009680259,0.0002379722,0.0004506567,0.00003266419,0.0002380619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3717119,"threshold_uncertainty_score":0.6068655,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137996608","doi":"10.1158/0008-5472.can-06-3332","title":"Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":524,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; Immunovaccine (Canada)","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Aging; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Michael Smith Health Research BC; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Oregon National Primate Research Center; National Institute of Child Health and Human Development; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Androgen; Androgen deprivation therapy; Medicine; Androgen receptor; Internal medicine; Endocrinology; Testosterone (patch); Prostate; TMPRSS2; LNCaP; Cancer research; Cancer; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.0799958214474921,"gpt":0.4127913581025604,"spread":0.3327955366550683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008929936,0.0002755879,0.0003621012,0.0003621997,0.0006242426,0.0001218489,0.0001466719,0.0001662765,0.0002730986],"category_scores_gemma":[0.00005306472,0.0002057335,0.00009229756,0.0006491066,0.0005492648,0.000180056,0.0001032568,0.0003930518,0.000005248777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005448938,"about_ca_system_score_gemma":0.000779464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001861072,"about_ca_topic_score_gemma":0.0003067793,"domain_scores_codex":[0.9970766,0.00009772478,0.0004084793,0.0007288626,0.0006162548,0.001072056],"domain_scores_gemma":[0.9976617,0.0002884378,0.00007872721,0.0004915328,0.0009381325,0.0005414799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.006734997,0.0002073065,0.04184464,0.0004439134,0.0001848805,0.00005018919,0.001365425,0.00000442491,0.9264232,0.00004356344,0.001276102,0.02142137],"study_design_scores_gemma":[0.006515085,0.001180908,0.1794339,0.0006704216,0.0001810549,0.0000646585,0.0007703273,0.00006402531,0.80411,0.0005124373,0.00612768,0.0003694639],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9593446,0.0301387,0.0001238011,0.006037617,0.0001040579,0.003503541,0.0005928628,0.00005935764,0.00009551703],"genre_scores_gemma":[0.9897304,0.003133027,0.0006369299,0.0001641095,0.0002355553,0.0034251,0.0001849817,0.00007516532,0.002414767],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1375893,"threshold_uncertainty_score":0.8389567,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789730857","doi":"10.1158/2159-8290.cd-17-0937","title":"Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Interior Health; BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Astellas Pharma; Emil Aaltosen Säätiö; Prostate Cancer Canada; DOD Prostate Cancer Research Program; Terry Fox Research Institute; Movember Foundation; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Androgen receptor; Cancer; Liquid biopsy; Medicine; Oncology; Internal medicine; Circulating tumor cell; Cancer research; Biomarker; Cancer biomarkers; Exome sequencing; Gene; Biology; Mutation; Genetics; Metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.01801108254339182,"gpt":0.2996990652203911,"spread":0.2816879826769993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000136571,0.0002229052,0.0003442725,0.0001388078,0.0001130461,0.00008406627,0.00007755506,0.00003931671,0.00005105582],"category_scores_gemma":[0.00001723905,0.0001649936,0.00002781958,0.0003967812,0.0002539523,0.0002829635,0.00007184925,0.0001981804,0.00001142453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008204933,"about_ca_system_score_gemma":0.0008316107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007967901,"about_ca_topic_score_gemma":0.0045598,"domain_scores_codex":[0.9984204,0.0000280169,0.0002478626,0.0005240918,0.0002496113,0.0005300092],"domain_scores_gemma":[0.9993083,0.00002840445,0.00008043363,0.0002651766,0.000115015,0.0002026976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01381918,0.0001910181,0.8164281,0.0009844726,0.0003659961,0.001355461,0.008995594,0.0004075936,0.14562,0.0001923903,0.001843143,0.009796992],"study_design_scores_gemma":[0.0125136,0.001362089,0.8857852,0.005473043,0.0002441366,0.00009567798,0.001347501,0.0003623674,0.07726351,0.0002727594,0.0142883,0.0009917725],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905329,0.005334952,0.00003481533,0.001679004,0.0001807196,0.0009708951,0.00009863913,0.00003182382,0.001136266],"genre_scores_gemma":[0.9889069,0.001131301,0.0002124109,0.000838414,0.0002701481,0.0004266819,0.00001325563,0.00005402733,0.008146919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06935712,"threshold_uncertainty_score":0.6728246,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2118238803","doi":"10.1016/j.ccr.2010.04.027","title":"Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor","year":2010,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Transactivation; Androgen receptor; Prostate cancer; Androgen; Cancer research; Receptor; Small molecule; Androgen Receptor Antagonists; Endocrinology; Biology; Internal medicine; Chemistry; Gene; Medicine; Cancer; Transcription factor; Biochemistry; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.01518591805299086,"gpt":0.2911771918174362,"spread":0.2759912737644454,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001413274,0.0001840677,0.0003318199,0.00002978451,0.00006640064,0.000005739902,0.0002538008,0.0001053699,0.0002987857],"category_scores_gemma":[0.00001555968,0.00008683564,0.0001718579,0.0002519216,0.0004231814,0.00003498164,0.0001209363,0.0002932199,0.000001265198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001378201,"about_ca_system_score_gemma":0.0007261244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001089616,"about_ca_topic_score_gemma":0.0006474162,"domain_scores_codex":[0.9986558,0.00007092784,0.0003509911,0.0002489878,0.0003951306,0.0002781819],"domain_scores_gemma":[0.9987918,0.00002946475,0.0003444954,0.0004916838,0.0002377123,0.0001048453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005750002,0.0002422997,0.03097938,0.0005108818,0.00005244228,0.000003353136,0.001166352,0.000001219385,0.9536834,0.000004887377,0.006314258,0.006466485],"study_design_scores_gemma":[0.002154991,0.0002386748,0.003029461,0.0007216191,0.00008648176,0.000003385285,0.0002291957,0.00001039494,0.9875479,0.00001048076,0.005878406,0.00008900047],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875697,0.008566121,5.302339e-7,0.0006770549,0.0008144517,0.001019922,0.0005154976,0.00000684458,0.0008298811],"genre_scores_gemma":[0.9938853,0.001434244,0.00004541801,0.00003788922,0.0001066499,0.0001676189,0.00001681775,0.00002657887,0.004279416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03386446,"threshold_uncertainty_score":0.3541054,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1549619413","doi":"10.1038/ng.3315","title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","year":2015,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":489,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Genome British Columbia; Université Laval; University of Toronto; University Health Network; Toronto General Hospital; BC Cancer Agency; Simon Fraser University; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Cancer Research UK","keywords":"Biology; Prostate cancer; Genomics; Cancer; Genetic heterogeneity; Prostate; Computational biology; Tumor heterogeneity; Genome; Single-nucleotide polymorphism; Genetics; Gene; Genotype; Phenotype","retraction":null,"screen_n_in":null,"score":{"opus":0.03187420802986779,"gpt":0.3501329320635392,"spread":0.3182587240336714,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001892999,0.0002095375,0.0002746425,0.0000795242,0.00006215395,0.00002956403,0.0001270874,0.0003515063,0.00004183726],"category_scores_gemma":[0.00004656595,0.0001541336,0.00008050451,0.0001661713,0.0001372897,0.00002683036,0.00009896728,0.0006700592,0.00006013485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000360128,"about_ca_system_score_gemma":0.0007478193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002105777,"about_ca_topic_score_gemma":0.0004196673,"domain_scores_codex":[0.9984219,0.00004861562,0.0002259997,0.0003743635,0.000526754,0.0004023461],"domain_scores_gemma":[0.9988163,0.00001300435,0.00006514777,0.0003423279,0.0003130609,0.0004501255],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005233601,0.0004709478,0.896707,0.0002282453,0.0005178509,0.0004721022,0.002148943,0.001114525,0.01714685,0.00001511144,0.01085374,0.06509109],"study_design_scores_gemma":[0.03545737,0.00278119,0.2159905,0.0002856152,0.0006649764,0.0002499857,0.0004428987,0.02129632,0.5100701,0.0004785381,0.2111162,0.001166282],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711295,0.02558132,0.00009173864,0.001019795,0.0008671087,0.0007709899,0.0000806827,0.0000641311,0.0003947292],"genre_scores_gemma":[0.9937958,0.001049226,0.002211509,0.0006628393,0.000614973,0.00006583421,0.00009659956,0.00004584589,0.001457353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6807165,"threshold_uncertainty_score":0.6285387,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160463964","doi":"10.1158/1078-0432.ccr-14-2666","title":"Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Prostate cancer; Androgen receptor; Medicine; Cancer research; Prostate; Androgen; Cancer; Castration; Oncology; Internal medicine; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.2777102049017103,"gpt":0.5002984513579463,"spread":0.222588246456236,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004228184,0.0001974184,0.000585645,0.0004622063,0.0001034013,0.00003948536,0.0003325237,0.0002100153,0.0001916445],"category_scores_gemma":[0.0007756774,0.0001639863,0.0001214219,0.001795161,0.0006281409,0.0001536604,0.0001435307,0.0008565205,0.00001311807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139066,"about_ca_system_score_gemma":0.004186588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003593834,"about_ca_topic_score_gemma":0.01652407,"domain_scores_codex":[0.9954748,0.0007270283,0.001124717,0.000655677,0.001230098,0.0007876492],"domain_scores_gemma":[0.9973515,0.000504287,0.0001681909,0.0006746516,0.0008880203,0.0004133279],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01428895,0.001833126,0.8154408,0.0009077794,0.0003675577,0.0003759279,0.004047058,0.0001570214,0.1394646,0.0001951983,0.0119436,0.01097838],"study_design_scores_gemma":[0.06073011,0.003344798,0.8007284,0.003730774,0.0001832958,0.000008164749,0.00628937,0.001028038,0.1029055,0.005629691,0.01431948,0.001102365],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9663246,0.02184895,0.000002486555,0.006688684,0.0002060982,0.001764397,0.0001596452,0.00002055129,0.002984639],"genre_scores_gemma":[0.9910774,0.004731101,0.0004935679,0.00007491542,0.0001885431,0.000828277,0.00005086812,0.00004429282,0.002511033],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04644116,"threshold_uncertainty_score":0.9220818,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2540786849","doi":"10.1158/2159-8290.cd-15-1263","title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":444,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Androgen receptor; Cancer research; Neuroendocrine differentiation; Transcription factor; SOX2; Prostate; Enzalutamide; In vivo; Tramp; Biology; Cancer; Medicine; Internal medicine; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03884735603184115,"gpt":0.3067152536351832,"spread":0.2678678976033421,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004182369,0.0001801072,0.0002506873,0.00008787528,0.00006717497,0.00004492725,0.0001194731,0.00002964988,0.0003913513],"category_scores_gemma":[0.000009083506,0.00009002392,0.00009461215,0.0001662302,0.0001310887,0.0006343285,0.00002894571,0.0001217334,0.000003801602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003036477,"about_ca_system_score_gemma":0.0001807289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004552068,"about_ca_topic_score_gemma":0.0005077947,"domain_scores_codex":[0.9986002,0.00007854724,0.0002841284,0.0003329414,0.0003298482,0.0003743604],"domain_scores_gemma":[0.9993795,0.00004249573,0.00009792935,0.0002882613,0.00009224627,0.00009957774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00242134,0.0001345411,0.4936869,0.0001179279,0.00009570634,0.00001287035,0.0008145703,0.000006346564,0.464903,0.00001003659,0.0007320687,0.03706475],"study_design_scores_gemma":[0.006601629,0.0004448193,0.5012792,0.0003994041,0.00008558805,0.000003956597,0.0001636377,0.0001630101,0.4865427,0.00006352748,0.0040604,0.0001921357],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884036,0.002449283,0.00001831637,0.007313601,0.0004254202,0.0007560201,0.0005822463,0.00001935449,0.00003214472],"genre_scores_gemma":[0.9826283,0.009840219,0.000003645984,0.0001537153,0.0001295983,0.0002816126,0.00004243617,0.00003044947,0.006890007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03687261,"threshold_uncertainty_score":0.4285023,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121098984","doi":"10.1126/scitranslmed.aac9511","title":"Plasma <i>AR</i> and abiraterone-resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":441,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Prostate Cancer UK; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Abiraterone; Prostate cancer; Medicine; Cancer; Abiraterone acetate; Prostate; Oncology; Internal medicine; Urology; Androgen deprivation therapy; Androgen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.06533960079360934,"gpt":0.36954620893229,"spread":0.3042066081386806,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007054965,0.0001248287,0.000210102,0.00020846,0.0001558269,0.00002005207,0.00009074873,0.00002551978,0.0001357979],"category_scores_gemma":[0.00006748393,0.00007740911,0.00001717489,0.0006164878,0.001677143,0.0002392847,0.0000163518,0.0001248077,0.00001617886],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001016097,"about_ca_system_score_gemma":0.001033468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001748596,"about_ca_topic_score_gemma":0.00004460851,"domain_scores_codex":[0.9980055,0.00001634206,0.0002074352,0.0003392215,0.001096061,0.0003354553],"domain_scores_gemma":[0.9989273,0.00004007804,0.00003696877,0.0001330701,0.0003385283,0.0005240528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.008595761,0.0003968941,0.2685428,0.0004981089,0.0001749081,0.0003310808,0.02297193,0.0001651573,0.5845973,0.006660731,0.009189886,0.09787543],"study_design_scores_gemma":[0.06601593,0.006407367,0.7428599,0.002263968,0.000507954,0.0004048334,0.00420133,0.01019441,0.06507748,0.01221956,0.08875783,0.00108941],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9278277,0.005059764,0.00003759702,0.05569247,0.0003126299,0.0006099943,0.00002894745,0.0000444785,0.01038643],"genre_scores_gemma":[0.995864,0.0003459076,0.0004711909,0.0004036528,0.0001907836,0.00004739656,0.00001848907,0.00001020498,0.002648345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5195199,"threshold_uncertainty_score":0.6179504,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2788051020","doi":"10.1038/nrurol.2018.22","title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":437,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Enzalutamide; Medicine; Neuroendocrine differentiation; Androgen receptor; Cancer research; Prostate; Phenotype; Reprogramming; Cancer; Oncology; Bioinformatics; Internal medicine; Cell; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03822869314807698,"gpt":0.3845540219264816,"spread":0.3463253287784047,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005643904,0.0005047134,0.003086899,0.0002212216,0.00007575403,0.00001850926,0.0002379274,0.0003345172,0.0001507805],"category_scores_gemma":[0.0005045363,0.0002276396,0.0003570249,0.0005573637,0.0006004709,0.0000303534,0.0001933028,0.002686176,0.00009099519],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001227957,"about_ca_system_score_gemma":0.0003968846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003762725,"about_ca_topic_score_gemma":0.0000544193,"domain_scores_codex":[0.9969147,0.0009106121,0.0007220027,0.0006823147,0.0002124914,0.0005579194],"domain_scores_gemma":[0.9985828,0.0004363265,0.0003252023,0.000439168,0.00008141725,0.0001350356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005066977,0.00006768135,0.0001027811,0.02545852,0.0001983085,0.0005059845,0.00004246405,4.427843e-8,6.986102e-7,0.0002180617,0.005033382,0.9678653],"study_design_scores_gemma":[0.002131491,0.0002041637,0.00002310867,0.00418424,0.001561184,0.0002873699,7.914894e-7,0.000006657086,0.000001050113,0.00005859674,0.9913793,0.0001621071],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002992074,0.9920927,8.442141e-7,0.00198523,0.0004257271,0.00488437,0.00003644653,0.00002039036,0.000524384],"genre_scores_gemma":[0.0000452889,0.9961087,0.00002200465,0.0009131656,0.0005601359,0.001024892,0.0000877366,0.00005654988,0.001181509],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9863459,"threshold_uncertainty_score":0.9996147,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3032046986","doi":"10.1056/nejmoa2004325","title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Medicine; Luteinizing hormone; Internal medicine; Androgen; Hormone antagonist; Hormone; Endocrinology; Gonadotropin-releasing hormone; Leuprorelin; Antagonist; Oncology; Cancer; Endocrine system; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.05957229224554349,"gpt":0.3705046643917067,"spread":0.3109323721461631,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039241,0.0001149108,0.0004220053,0.0001296707,0.00002588039,0.000005323152,0.00007222169,0.00004208267,0.0001141907],"category_scores_gemma":[0.0001964672,0.000066138,0.00005555394,0.0002598027,0.00004941265,0.000102274,0.000008185431,0.0002454105,9.902308e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008613043,"about_ca_system_score_gemma":0.0003582936,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006240699,"about_ca_topic_score_gemma":0.00002272798,"domain_scores_codex":[0.9989073,0.00002584762,0.0003960625,0.0001291782,0.0003389413,0.0002026544],"domain_scores_gemma":[0.999154,0.00006844893,0.0001709469,0.00007260188,0.0002376333,0.0002963951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02854526,0.00009384489,0.1383062,0.0001184507,0.0001658592,0.0002474215,0.005491641,0.0001020044,0.0291973,0.00003380001,0.008975836,0.7887223],"study_design_scores_gemma":[0.5239642,0.02020105,0.051866,0.001359492,0.0001689347,0.0002435529,0.0007902111,0.0005508643,0.02428519,0.001229507,0.3751121,0.0002289748],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8862519,0.01181594,0.0001582753,0.1007731,0.0002233793,0.0006349407,0.000004237018,0.000009898538,0.0001283217],"genre_scores_gemma":[0.9785694,0.01599486,0.0007777936,0.001845672,0.002329346,0.00001827346,0.00001634947,0.00002203918,0.0004262346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7884934,"threshold_uncertainty_score":0.269703,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1995156882","doi":"10.1097/01.pas.0000213424.38503.aa","title":"TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion","year":2007,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":431,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Aging; Johns Hopkins University","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Malignancy; Medicine; Prostate; Cancer; Erg; Intraepithelial neoplasia; Fluorescence in situ hybridization; PCA3; Pathology; Oncology; Cancer research; Internal medicine; Biology; Disease; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.0175685097098907,"gpt":0.326369672706825,"spread":0.3088011629969343,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001415947,0.0001572476,0.000528414,0.0001584147,0.0001023547,0.00001242867,0.0001649532,0.00005042124,0.00004593169],"category_scores_gemma":[0.00004366225,0.00007652801,0.0001244313,0.0004817772,0.0006668579,0.00007534465,0.00004608315,0.0005408385,0.00000425933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000192807,"about_ca_system_score_gemma":0.000261602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008749519,"about_ca_topic_score_gemma":0.00001813116,"domain_scores_codex":[0.9980938,0.0003435922,0.0003972986,0.0001802089,0.0005390079,0.0004461326],"domain_scores_gemma":[0.9984172,0.0001821742,0.0005124991,0.0002085364,0.0003654914,0.0003140789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05069223,0.001922971,0.3723636,0.00003015348,0.0008198459,0.08799344,0.003506317,0.0002721035,0.1401753,0.000134738,0.000182406,0.3419069],"study_design_scores_gemma":[0.01433295,0.04279969,0.9090824,0.0006111411,0.0005486622,0.0079631,0.001791353,0.00007648543,0.02006464,0.0003593804,0.0019594,0.0004108739],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946677,0.0009764872,0.0001141525,0.003694449,0.00007400507,0.0002432334,0.000005596798,0.0000158385,0.0002085318],"genre_scores_gemma":[0.9977167,0.001466104,0.0001280766,0.0002795824,0.0001153958,0.000005804857,0.000007821745,0.00002462032,0.0002558998],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5367187,"threshold_uncertainty_score":0.3120722,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3031020438","doi":"10.1056/nejmoa2003892","title":"Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":422,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Université de Montréal","funders":"Ipsen; Astellas Pharma; Janssen Scientific Affairs; Sanofi; Genentech; PharmaMar; AstraZeneca; Amgen; Pfizer; Cilag; Northwestern University","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Overall survival; Internal medicine; Cancer; Urology; Androgen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.04826896524351373,"gpt":0.3394223659720499,"spread":0.2911534007285362,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005059736,0.000120028,0.0004560936,0.0001297966,0.00002581765,0.000009879806,0.00005085932,0.00002971002,0.000204379],"category_scores_gemma":[0.0002668634,0.00007083268,0.00003036764,0.0002199232,0.0001033123,0.0000874563,0.00001423997,0.000327542,0.000001479579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006525661,"about_ca_system_score_gemma":0.0004293211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003552093,"about_ca_topic_score_gemma":0.0002150954,"domain_scores_codex":[0.9987056,0.0000721708,0.0004352459,0.0001262325,0.0004681668,0.0001925637],"domain_scores_gemma":[0.9990573,0.0001374159,0.0001460602,0.0000603335,0.0001340394,0.0004648426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02827784,0.0002106536,0.3671541,0.000723447,0.0005989519,0.007585024,0.02519626,0.0001541298,0.1832293,0.0002122538,0.00863272,0.3780254],"study_design_scores_gemma":[0.4359862,0.01741084,0.4329656,0.003277387,0.0009619432,0.001355467,0.005601626,0.0007159245,0.008979741,0.001074162,0.09119768,0.0004734282],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9094318,0.009772859,0.00004611179,0.07980125,0.0001800505,0.0002388777,0.000008048381,0.000005765576,0.0005152471],"genre_scores_gemma":[0.9921282,0.004910422,0.0003508059,0.0006626936,0.001533109,0.000002722073,0.000005857102,0.00001331419,0.0003928669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4077083,"threshold_uncertainty_score":0.2888473,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2489425084","doi":"10.1016/j.eururo.2016.07.032","title":"Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study","year":2016,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":419,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Chemotherapy; Internal medicine; Docetaxel; Urology; Gynecology; Cancer; Androgen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.02552419789789771,"gpt":0.3359378952628794,"spread":0.3104136973649816,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004982217,0.0001543194,0.0004039917,0.0002481921,0.00004579061,0.000007695868,0.0001507363,0.00001461469,0.0002243002],"category_scores_gemma":[0.00004446116,0.00006808287,0.00007979196,0.000757512,0.0002110637,0.00004638744,0.00004231967,0.0001144049,0.00000695691],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009170779,"about_ca_system_score_gemma":0.0001856795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001638458,"about_ca_topic_score_gemma":0.000669256,"domain_scores_codex":[0.998184,0.0005937396,0.0003362625,0.0003344332,0.0002714684,0.0002800467],"domain_scores_gemma":[0.9991238,0.0001062863,0.0001569533,0.000433597,0.000107437,0.00007200224],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02936999,0.006239229,0.6577779,0.0001144699,0.01184062,0.001634842,0.01389977,0.0002479239,0.2118217,0.00007549798,0.0005563786,0.06642164],"study_design_scores_gemma":[0.02323962,0.004483933,0.9631703,0.00004419815,0.002259031,0.00001028632,0.0005855229,0.0001587748,0.005024325,0.00001776003,0.0008763907,0.0001298352],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931764,0.0004714508,0.00001711844,0.002891812,0.00001959368,0.001207122,0.00005998406,0.00001717683,0.002139338],"genre_scores_gemma":[0.9965562,0.0002056327,0.00003310241,0.000157808,0.00001949606,0.00007196477,0.000008721425,0.00002774456,0.002919385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3053924,"threshold_uncertainty_score":0.2776339,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4321079951","doi":"10.1056/nejmoa2214676","title":"Rucaparib or Physician’s Choice in Metastatic Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":414,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; CancerCare Manitoba; Sunnybrook Health Science Centre; Research Institute in Oncology and Hematology","funders":"National Cancer Institute; Clovis Oncology","keywords":"Prostate cancer; Medicine; Oncology; Cancer; Prostate; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0689749689444052,"gpt":0.3971037382452716,"spread":0.3281287693008664,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007864899,0.0001539856,0.0006026896,0.0004968876,0.00003527603,0.000008681503,0.0001065365,0.00003167352,0.0003396732],"category_scores_gemma":[0.0004015355,0.00007856567,0.00006130425,0.0009529488,0.0001012983,0.0001140312,0.00002179778,0.0004322373,0.00002013155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001567485,"about_ca_system_score_gemma":0.0007535296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00069601,"about_ca_topic_score_gemma":0.0004483042,"domain_scores_codex":[0.9982798,0.00007893486,0.0004908727,0.0001426578,0.0006479805,0.000359733],"domain_scores_gemma":[0.9988328,0.0003316861,0.0001912003,0.0001327808,0.0001833651,0.0003281506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01102934,0.0003073571,0.1306241,0.000538756,0.0006818931,0.007964754,0.007125877,0.0002091459,0.01334951,0.00004311906,0.1122389,0.7158872],"study_design_scores_gemma":[0.3425552,0.008510736,0.2473933,0.00616705,0.0009196312,0.001055157,0.002238376,0.0005700956,0.003944132,0.001447266,0.3848305,0.0003685702],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9410697,0.006152329,0.00001184733,0.05061222,0.000722678,0.0004396451,0.000008161357,0.00002827056,0.0009551819],"genre_scores_gemma":[0.9627486,0.01139273,0.0001725308,0.001427945,0.004756179,0.00002221037,0.00002515356,0.00004237022,0.01941223],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7155187,"threshold_uncertainty_score":0.3719184,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2806421431","doi":"10.1016/s1470-2045(18)30365-6","title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Enzalutamide; PARP inhibitor; Placebo; Clinical endpoint; Docetaxel; Population; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.063617209979282,"gpt":0.3828651709096185,"spread":0.3192479609303365,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009477966,0.0002744459,0.001284415,0.0001417276,0.0001745739,0.00004397904,0.0001701367,0.00007391293,0.0001931264],"category_scores_gemma":[0.00003678713,0.0001267645,0.00005827348,0.0003685029,0.0005097506,0.0001058433,0.00002481538,0.0003506474,0.0000227546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004132538,"about_ca_system_score_gemma":0.00112257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003716561,"about_ca_topic_score_gemma":0.003256829,"domain_scores_codex":[0.9977214,0.0003794297,0.0004715344,0.0003666703,0.0004233554,0.0006375573],"domain_scores_gemma":[0.9986042,0.0002642942,0.000270338,0.0003938541,0.0003217043,0.0001456153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.990548,0.001978936,0.002998464,0.0000622484,0.0007842664,0.0001291097,0.001175831,0.0000160463,0.0003216652,0.00006827464,0.0005472701,0.001369897],"study_design_scores_gemma":[0.9548543,0.04105736,0.001154525,0.0001045847,0.0005319158,0.000008342437,0.0001534145,0.00009402092,0.0007001543,0.00003906722,0.001146422,0.0001559095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981216,0.0002017394,0.00001220082,0.004527442,0.000183027,0.01222428,0.00005287662,0.00004164697,0.001540841],"genre_scores_gemma":[0.9935496,0.00009567144,0.0002251512,0.0003579934,0.0003955637,0.004039485,0.0001413563,0.00003512228,0.001160016],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03907843,"threshold_uncertainty_score":0.5169308,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2911490798","doi":"10.1016/s1470-2045(18)30860-x","title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":397,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Bayer Fund","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Abiraterone; Placebo; Urology; Radium-223; Internal medicine; Castration; Prednisolone; Oncology; Cancer; Androgen deprivation therapy; Bone metastasis; Hormone; Alternative medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04740764339260094,"gpt":0.3646799658367788,"spread":0.3172723224441779,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008241965,0.0002362104,0.00131488,0.0001703551,0.00007531748,0.00002988273,0.00007971226,0.00009245238,0.0001492301],"category_scores_gemma":[0.00005701284,0.0001222629,0.00004242773,0.0002465689,0.0002147948,0.0001326728,0.00005250451,0.0002310948,0.000004644142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001790789,"about_ca_system_score_gemma":0.0005482538,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002999663,"about_ca_topic_score_gemma":0.0009165573,"domain_scores_codex":[0.9981055,0.0002792534,0.0005072118,0.0003770461,0.0003004543,0.0004304887],"domain_scores_gemma":[0.9988095,0.0003418453,0.0002694989,0.0002722705,0.0001592782,0.0001475783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9865565,0.001369603,0.001783301,0.0002075269,0.0004744151,0.00004870662,0.001327772,0.00003668633,0.00354208,0.00001903001,0.0003658103,0.004268527],"study_design_scores_gemma":[0.9760144,0.01726254,0.003051037,0.0001778078,0.000395101,0.00001455814,0.0001799984,0.00007127198,0.001789079,0.00001601814,0.0008874238,0.0001408033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824536,0.001067922,0.000005315525,0.002866053,0.0001100232,0.01289128,0.0004290408,0.00001947731,0.0001572936],"genre_scores_gemma":[0.9948187,0.0007931552,0.0002969808,0.0001593566,0.0001454428,0.002405794,0.0002049512,0.00002610042,0.001149554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01589294,"threshold_uncertainty_score":0.4985738,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3011518560","doi":"10.1016/j.eururo.2020.01.012","title":"Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":395,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Medical Research Council; National Institute for Health and Care Research; Cancer Research UK","keywords":"Prostate cancer; Medicine; Management of prostate cancer; Prostate; Voting; Delphi method; Consensus conference; Cancer; Oncology; Gynecology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01720519341896556,"gpt":0.2828804490915681,"spread":0.2656752556726026,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001324863,0.0002087806,0.0004079702,0.00004299631,0.00005703863,0.000004844095,0.0001985977,0.00002818291,0.00009992679],"category_scores_gemma":[0.00003404218,0.0001254022,0.0000662003,0.0002996243,0.0004363006,0.00003680974,0.0001951955,0.0002269708,0.00000912715],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000500304,"about_ca_system_score_gemma":0.0002531152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004115598,"about_ca_topic_score_gemma":0.00001070119,"domain_scores_codex":[0.9981937,0.0001656008,0.0004538482,0.0004537646,0.0003708488,0.0003622147],"domain_scores_gemma":[0.9985145,0.00002968502,0.0004359524,0.0004349422,0.0004438651,0.000141055],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.027683,0.0006315987,0.8508348,0.001582264,0.001418033,0.002810583,0.003819705,0.001735534,0.007836719,0.0002154198,0.003921473,0.09751087],"study_design_scores_gemma":[0.01663725,0.003647578,0.9156749,0.0004396107,0.0004607771,0.00002724783,0.0003069686,0.00007882147,0.00874084,0.00002249723,0.05365333,0.0003102071],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9809373,0.001886313,0.000006687038,0.009572878,0.0001838514,0.001945741,0.0002395231,0.00003847367,0.005189246],"genre_scores_gemma":[0.9937338,0.001660651,0.0002676164,0.000468304,0.0000264945,0.00007300971,0.00006573948,0.00004791098,0.003656429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09720066,"threshold_uncertainty_score":0.5113752,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2964673115","doi":"10.1158/1078-0432.ccr-19-1423","title":"The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Lineage (genetic); Cancer; Resistance (ecology); Medicine; Cancer therapy; Biology; Internal medicine; Genetics; Ecology","retraction":null,"screen_n_in":null,"score":{"opus":0.1459517182911886,"gpt":0.5267830732056228,"spread":0.3808313549144342,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002765472,0.0001542473,0.0005032504,0.0001508555,0.0001472059,0.00003697764,0.0003811175,0.0001340999,0.0004957248],"category_scores_gemma":[0.000512291,0.00008895103,0.0001537376,0.0008782211,0.0008610744,0.00007439348,0.0001582565,0.001372381,0.00006975241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003182284,"about_ca_system_score_gemma":0.001679179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001241506,"about_ca_topic_score_gemma":0.001863305,"domain_scores_codex":[0.9963215,0.0004928121,0.0007127125,0.0005243493,0.001133077,0.0008155328],"domain_scores_gemma":[0.9961531,0.002272468,0.0001127035,0.0005258939,0.0007047867,0.0002310204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01834038,0.000498871,0.9152297,0.0001732034,0.0001536367,0.00003481433,0.0003384478,0.00001412752,0.006227902,0.0003594833,0.002461525,0.05616791],"study_design_scores_gemma":[0.01337812,0.001852934,0.564806,0.00117773,0.00002118455,0.000001368284,0.0008698072,0.0004818909,0.06101418,0.001445308,0.3546897,0.0002617904],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9529132,0.0349048,2.946393e-7,0.004098847,0.0002164847,0.001834989,0.00005133885,0.00001804814,0.005961963],"genre_scores_gemma":[0.897692,0.07933275,0.00002202684,0.00008909259,0.0002612347,0.0005402646,0.000005844812,0.00003241904,0.02202436],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3522281,"threshold_uncertainty_score":0.5962389,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2048274452","doi":"10.1016/j.eururo.2009.04.036","title":"ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice","year":2009,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"TMPRSS2; Prostate cancer; Medicine; Fusion gene; Cancer; Population; Prostate; Prostatectomy; Oncology; Cancer research; Internal medicine; Bioinformatics; Gene; Disease; Genetics; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1047867623423824,"gpt":0.4648146394172862,"spread":0.3600278770749039,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001097892,0.0004521139,0.001870686,0.000328694,0.00006662219,0.00004696146,0.0003566107,0.0002026762,0.0001250907],"category_scores_gemma":[0.0009869077,0.000319541,0.0003555371,0.0004865171,0.0001290469,0.0001179953,0.0003586104,0.001488373,0.00118457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002302253,"about_ca_system_score_gemma":0.00103116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002019428,"about_ca_topic_score_gemma":0.00006505607,"domain_scores_codex":[0.9946867,0.00220661,0.001113272,0.001036609,0.0003045021,0.0006522802],"domain_scores_gemma":[0.9974815,0.0009171289,0.0003217775,0.0007832715,0.000100762,0.0003955874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007516732,0.0004492715,0.0003016594,0.0004000935,0.0003036211,0.008432874,0.0001510151,0.000001651499,0.000003868464,0.000009009666,0.009642228,0.979553],"study_design_scores_gemma":[0.001566416,0.001242304,0.002879853,0.001708742,0.00111402,0.0001439427,0.00001120451,0.000001068066,6.128727e-7,0.000008179699,0.9910625,0.0002611403],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006749687,0.9793391,0.000007190562,0.005463541,0.0006554459,0.001915813,0.0003131653,0.00005952437,0.01157123],"genre_scores_gemma":[0.00008112177,0.9883977,0.0005147737,0.003568769,0.001208274,0.0001043748,0.0007701787,0.0001195494,0.00523528],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9814203,"threshold_uncertainty_score":0.9999257,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2403998898","doi":"10.1001/jamaoncol.2016.0494","title":"Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute","keywords":"Enzalutamide; Prostate cancer; Medicine; Interquartile range; Oncology; Internal medicine; Cell-free fetal DNA; Prostate-specific antigen; Cancer; Androgen deprivation therapy; Androgen receptor; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02452938334777873,"gpt":0.3308476599576475,"spread":0.3063182766098688,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002550051,0.0001159133,0.0002565492,0.0001964137,0.0000496671,0.00001799919,0.00007663265,0.000115742,0.0001020287],"category_scores_gemma":[0.00008840636,0.00007822253,0.00002318606,0.0001791594,0.0001426795,0.0001196049,0.0000520131,0.0001647524,0.00001194038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001030824,"about_ca_system_score_gemma":0.0007970233,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005483668,"about_ca_topic_score_gemma":0.03588338,"domain_scores_codex":[0.9988305,0.0001040243,0.0002962807,0.0003035322,0.0001251486,0.0003405103],"domain_scores_gemma":[0.999348,0.0001916226,0.00006382632,0.0002274858,0.00006505114,0.0001039963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.006173318,0.0004461355,0.1773841,0.0001971934,0.0000406572,0.00117485,0.00353038,0.000006285965,0.7819175,0.001194623,0.005799318,0.0221357],"study_design_scores_gemma":[0.02583379,0.0008780787,0.8890166,0.0004739781,0.00003775886,0.00002257033,0.000420293,0.00002667756,0.02840983,0.003397026,0.05124104,0.000242415],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9604585,0.003353446,0.000003455905,0.02886661,0.00008820726,0.0006701549,0.00007924946,0.00001449716,0.006465864],"genre_scores_gemma":[0.986956,0.002559217,0.0004726403,0.0003500611,0.0001065338,0.0003622188,0.0000129591,0.00001591288,0.009164471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7535076,"threshold_uncertainty_score":0.9817092,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}